We exist to improve the lives
of everyone affected by epilepsy

Retigabine (Trobalt) to be discontinued in 2017

3 Oct 2016

GlaxoSmithKline (GSK), the manufacturer of retigabine (brand name Trobalt), has announced it will permanently stop making this medicine from June 2017.

GSK says it is discontinuing this medicine for commercial reasons. Only around 1,500 people worldwide currently take this medicine, and this number is getting smaller as doctors very rarely prescribe it.

GSK has advised doctors to start looking for other suitable medicines for any patients taking retigabine as soon as possible. It has told doctors that all patients should have stopped taking retigabine by the end of June 2017 at the latest.

If you take retigabine, your epilepsy specialist should talk to you about how to safely stop taking this medicine in plenty of time before June 2017. They may suggest switching you to an alternative treatment. If you are not due to see an epilepsy specialist in the near future, it is important to ask your GP to refer you.

There are no comments yet. Be the first to comment...

Question about your epilepsy?

Use our email helpline service -- your question will be sent directly to our trained helpline advisors who will reply to you. If you post a question about your epilepsy as a comment on a page, it may not be replied to so please use the email helpline service.

Want to talk to other people with epilepsy?

Take a look at forum4e our online community for people with epilepsy. Anyone with epilepsy over the age of 16 can join, from anywhere in the world.

Comment about this page?

We welcome feedback on the content of our website. If you have any comments about the page you were reading, then please complete the form below.

All comments are reviewed by a moderator before appearing on the site. Once the comment appears, your name and comment will be seen by other visitors to the site. Comments will be edited or deleted if they are offensive, libellous, slanderous, abusive, commercial or irrelevant. Comments may also be edited or deleted if they are not relevant to the page on which they are entered.

By making a comment through the website, you allow us to use the comment in our publicity without using your name. If we would like to use your name, we will email you to get your permission.

CAPTCHA
This question is for testing whether you are a human visitor and to prevent automated spam submissions.
By submitting this form, you accept the Mollom privacy policy.